Literature DB >> 30394973

A Patient With Schimmelpenning Syndrome and Mosaic KRAS Mutation.

Benjamin J Mitchell1, Gary F Rogers2, Benjamin C Wood2.   

Abstract

Schimmelpenning syndrome is a neurocutaneous disorder characterized by craniofacial nevus sebaceus that fall along embryonic cutaneous lines and tend to be associated with neurological, ocular, skeletal, and vascular abnormalities. We report a child with extensive nevus sebaceus of the scalp, face, and thorax and other unusual physical findings who was found to have a mosaic mutation of KRAS c.35G>A p.12D pathognomonic of Schimmelpenning syndrome.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30394973     DOI: 10.1097/SCS.0000000000004887

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  4 in total

1.  Oral HRAS Mutation in Orofacial Nevus Sebaceous Syndrome (Schimmelpenning-Feuerstein-Mims-Syndrome): A Case Report With a Literature Survey.

Authors:  Reinhard E Friedrich; Martin Gosau; Andreas M Luebke; Christian Hagel; Felix K Kohlrusch; Michael Hahn; Simon VON Kroge; Jan Hahn; Ilse Wieland; Martin Zenker
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  Identification of KRAS mutation in a patient with linear nevus sebaceous syndrome: a case report.

Authors:  Chun Pan; Xiaowei Zhou; Anlan Hong; Fang Fang; Yan Wang
Journal:  BMC Med Genomics       Date:  2020-12-12       Impact factor: 3.063

3.  Identification of a recurrent mosaic KRAS variant in brain tissue from an individual with nevus sebaceous syndrome.

Authors:  Anthony J Penington; Ingrid E Scheffer; Michael S Hildebrand; Timothy E Green; Duncan MacGregor; Susan M Carden; Rebekah V Harris; Chelsee A Hewitt; Samuel F Berkovic
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-12-09

Review 4.  Sebaceous nevus of Jadassohn: review and clinical-surgical approach.

Authors:  Manoel Pereira da Silva Neto; Barbara Rodovalho de Assis; Gustavo Rodrigues Andrade
Journal:  An Bras Dermatol       Date:  2022-07-19       Impact factor: 2.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.